Trial
NCT01355575
Rifaximin in Fatty Liver Disease
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Imperial College London
Collaborators
National Health Service, United Kingdom
Condition
Nonalcoholic Fatty Liver Disease
Intervention
Rifaximin
Why stopped
Primary endpoint data review concluded no further patients required.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-28